Cellares

Cellares is a pioneering private company that has created a new category, the Integrated Development and Manufacturing Organization (IDMO), to industrialize cell therapy manufacturing. Its core value proposition is a fully automated, closed, and scalable platform (Cell Shuttle™, consumable cartridges, Cell Q™, and software) that promises a 10x productivity increase, up to 50% cost savings per batch, and significantly reduced failure rates compared to traditional CDMOs. With operational smart factories in the US, a planned European facility, and substantial Series D funding, Cellares is positioning itself as a critical infrastructure provider to enable the commercialization of next-generation cell therapies.

Fully integrated, closed, automated cell therapy manufacturing platform comprising the Cell Shuttle™ hardware, single-use consumable cartridges, Cell Q™ QC platform, and integrated software suite.

Cellares competes with traditional CDMOs (e.g., Lonza, Catalent, Thermo Fisher/Patheon) that are adding automated solutions, and with other tech-focused manufacturing startups. Its differentiation is the fully integrated 'factory-in-a-box' IDMO model, claiming superior scalability and cost savings versus the piecemeal automation approaches of incumbents.